Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for treatment-resistant OCD, BDD, and anorexia nervosa
ACTRN12624001160527Phase 2Not yet recruiting
- Sponsor
- Swinburne University of Technology
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in obsessive compulsive disorder (OCD), body dysmorphic disorder (BDD) and anorexia nervosa (AN), sponsored by Swinburne University of Technology. Primary endpoints: Obsessive-compulsive symptom severity, Body-dysmorphic symptom severity and 1 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
obsessive compulsive disorder (OCD)body dysmorphic disorder (BDD)anorexia nervosa (AN)
Beyond the preview
Go deeper on ACTRN12624001160527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001160527.